isoxazoles has been researched along with tamoxifen in 5 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 4 (80.00) | 24.3611 |
| 2020's | 1 (20.00) | 2.80 |
| Authors | Studies |
|---|---|
| Andò, S; Barone, I; Bonofiglio, D; Catalano, S; Fuqua, SA; Gelsomino, L; Giordano, C; Panza, S; Rizza, P; Vizza, D | 1 |
| Bouajila, J; Filali, I; Jannet, HB; Romdhane, A; Znati, M | 1 |
| Bhatnagar, S; Chandrasekhar, L; Kaushik, S; Lekshmi, A; Nair, M; Sanawar, R; Santhoshkumar, TR | 1 |
| Balachandran, P; Gowramma, B; Kalirajan, R; Pandiselvi, A | 1 |
| Blackshear, CP; Burcham, A; Chinta, MS; Cui, L; Foster, DS; Gulati, GS; Gurtner, GC; Hu, MS; Januszyk, M; Jones, RE; Kin, CJ; King, ME; Lerbs, T; Longaker, MT; Manjunath, A; Marshall, CD; Mascharak, S; Moore, AL; Nguyen, A; Norton, JA; Ransom, RC; Salhotra, A; Shelton, AA; Titan, AL; Wernig, G | 1 |
5 other study(ies) available for isoxazoles and tamoxifen
| Article | Year |
|---|---|
Farnesoid X receptor inhibits tamoxifen-resistant MCF-7 breast cancer cell growth through downregulation of HER2 expression.
Topics: Antineoplastic Agents, Hormonal; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Chenodeoxycholic Acid; Chromatin Immunoprecipitation; Down-Regulation; Drug Resistance, Neoplasm; Electrophoretic Mobility Shift Assay; Epidermal Growth Factor; Female; Gene Expression Regulation, Neoplastic; Humans; Isoxazoles; Mitogen-Activated Protein Kinase 3; NF-kappa B; Promoter Regions, Genetic; Receptor, ErbB-2; Receptors, Cytoplasmic and Nuclear; Receptors, Estrogen; Reverse Transcriptase Polymerase Chain Reaction; Signal Transduction; Tamoxifen | 2011 |
Synthesis of New Harmine Isoxazoles and Evaluation of their Potential Anti-Alzheimer, Anti-inflammatory, and Anticancer Activities.
Topics: Alzheimer Disease; Anti-Inflammatory Agents, Non-Steroidal; Antineoplastic Agents; Carbon-13 Magnetic Resonance Spectroscopy; Cholinesterase Inhibitors; Cycloaddition Reaction; Harmine; HCT116 Cells; Humans; Isoxazoles; Lipoxygenase Inhibitors; MCF-7 Cells; Peganum; Proton Magnetic Resonance Spectroscopy; Structure-Activity Relationship; Tamoxifen; Xanthine Oxidase | 2016 |
ER alpha selective chromone, isoxazolylchromones, induces ROS-mediated cell death without autophagy.
Topics: Antineoplastic Agents; Apoptosis; Autophagy; Binding Sites; Cell Cycle Checkpoints; Cell Line, Tumor; Chromones; Down-Regulation; Estrogen Receptor alpha; Estrogen Receptor beta; Humans; Isoxazoles; Ligands; Molecular Docking Simulation; Protein Structure, Tertiary; Reactive Oxygen Species; RNA Interference; RNA, Small Interfering; Signal Transduction; Tamoxifen | 2019 |
In-silico Design, ADMET Screening, MM-GBSA Binding Free Energy of Some Novel Isoxazole Substituted 9-Anilinoacridines as HER2 Inhibitors Targeting Breast Cancer.
Topics: Amsacrine; Antineoplastic Agents; Breast Neoplasms; Computer Simulation; Drug Design; Ethacridine; Female; Humans; Hydrogen Bonding; Isoxazoles; Models, Molecular; Molecular Dynamics Simulation; Receptor, ErbB-2; Structure-Activity Relationship; Tamoxifen | 2019 |
Elucidating the fundamental fibrotic processes driving abdominal adhesion formation.
Topics: Animals; Benzophenones; Cells, Cultured; CRISPR-Cas Systems; Doxycycline; Fibroblasts; Fluorescent Antibody Technique; Gastrointestinal Diseases; Humans; Immunohistochemistry; Isoxazoles; Liposomes; Mice; NIH 3T3 Cells; Parabiosis; RNA, Messenger; Tamoxifen; Tissue Adhesions | 2020 |